Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA

The introduction of point-of-care (POC) assays into clinical practice in patients with inflammatory disease enables on-demand therapeutic decision making. The aim of this study was to compare the POC test Quantum blue (Bühlmann Laboratories) for infliximab (IFX), adalimumab (ADL), and its anti-drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Toja-Camba, Francisco José, García-Quintanilla, Laura, Rodríguez-Martinez, Lorena, Tomine, Julia, Cajade-Pascual, Francisco, Feitosa, Carolina, Zarra-Ferro, Irene, Barreiro-De-Acosta, Manuel, González-López, Jaime, Mondelo-García, Cristina, Fernández-Ferreiro, Anxo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675023/
https://www.ncbi.nlm.nih.gov/pubmed/38004593
http://dx.doi.org/10.3390/pharmaceutics15112615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675023/
https://www.ncbi.nlm.nih.gov/pubmed/38004593
http://dx.doi.org/10.3390/pharmaceutics15112615

Ejemplares similares